0      0

AONN+ 2022 Annual Conference

Product Theater 8| Explore Data for an FDA-Approved Treatment Option in HR+, HER2- Breast Cancer in Certain Adjuvant or Metastatic SettingsPP-AL-US-2989 © Lilly USA, LLC 2021. All rights reserved.Presentation by Lilly

Nov 5, 2022 10:30am ‐ Nov 5, 2022 11:30am



You must be logged in and own this session in order to post comments.